Skip to content

免疫核心

US · IMCR #2968 按市值排名 上市于 2021
29.40 -0.08 -0.27%
实时 - 追踪5344个代码 - 心跳于496秒前 · 2026-10-16 19:30

✦ 量化股权信号 计算方式说明

减持
  • 最近一期（2026/Q3）披露持股的机构数量减少了3家。
  • 机构持股总比例下降了0.7个百分点。

机构持股

机构持股比例
102.11% -0.69pp
机构数量
154 -3
数据截至
2026/Q3 较上一报告期

持股变动 vs 资金流向

方向分歧

机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流入——两者方向出现分歧。

机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。

持股人类型

Mutual Fund52.09%
Hedge Fund45.77%
VC/PE Fund1.83%
Private Company1.04%
Public Company1.02%
Government Pension Fund0.34%
Individual/Insider0.10%

主要股东 截至 2026-06-30

Wellington Management Group 11.11% · 5.72M 股
RTW Investments, LP 9.46% · 4.87M 股
FMR 8.36% · 4.31M 股
PRIMECAP Management Company 7.06% · 3.64M 股
Bellevue Asset Management AG 5.41% · 2.79M 股
Tang Capital Management, LLC 5.14% · 2.65M 股
Vestal Point Capital, LP 3.50% · 1.80M 股
Two Sigma Investments, LP 3.20% · 1.65M 股
Millennium Management LLC 3.10% · 1.60M 股
Armistice Capital LLC 2.77% · 1.43M 股

条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。

内部人持股

共追踪50份申报 · 33次买入 · 17次卖出

姓名职务持股比例
Bahija Jallal Chief Executive Officer 0.05%
John Bell Independent Non-Executive Chairperson 0.03%
David Berman Head of Research & Development 0.02%
Tina Leger Chief Human Resources Officer & Director 0.00%
John Goll SVP, Finance & Chief Accounting Officer 0.00%
Peter Ratcliffe Independent Non-Executive Director 0.00%
Kristine Peterson Independent Non-Executive Director --
Roy Steven Herbst Independent Non-Executive Director --
Brian Di Donato CFO & Head of Strategy --
Baker Bros. Advisors LP -- --

内部人交易 最近的 Form 4 申报记录

日期姓名职务类型股数价格
2026-05-26 John Bell Independent Non-Executive Chairperson Other Derivative Acquisition +27,492 $28.52
2026-05-26 Kristine Peterson Independent Non-Executive Director Other Derivative Acquisition +27,492 $28.52
2026-05-26 Roy Steven Herbst Independent Non-Executive Director Other Derivative Acquisition +27,492 $28.52
2026-05-26 Peter Ratcliffe Independent Non-Executive Director Other Derivative Acquisition +27,492 $28.52
2026-05-26 William Pao Non-Executive Director Other Derivative Acquisition +27,492 $28.52
2026-05-26 Siddharth Kaul Independent Non-Executive Director Other Derivative Acquisition +27,492 $28.52
2026-03-10 David Berman Head of Research & Development Intent to Sell (Form 144) -11,832 $32.57
2026-02-17 Bahija Jallal Chief Executive Officer Derivative Exercise and Sale -11,474 $32.35
2026-02-17 Bahija Jallal Chief Executive Officer Intent to Sell (Form 144) -11,474 $32.35
2026-02-17 John Goll SVP, Finance & Chief Accounting Officer Derivative Exercise and Sale -698 $32.35
2026-02-17 Tina Leger Chief Human Resources Officer & Director Derivative Exercise and Sale -1,000 $32.35
2026-02-17 Tina Leger Chief Human Resources Officer & Director Intent to Sell (Form 144) -1,000 $32.35
2026-02-17 David Berman Head of Research & Development Derivative Exercise and Sale -5,965 $32.35
2026-02-17 David Berman Head of Research & Development Intent to Sell (Form 144) -5,965 $32.35
2026-02-16 Bahija Jallal Chief Executive Officer Other Derivative Acquisition +88,573 --
2026-02-16 Bahija Jallal Chief Executive Officer Other Derivative Acquisition +395,066 $32.38
2026-02-16 Bahija Jallal Chief Executive Officer Derivative Exercise and Retained +12,343 --
2026-02-16 John Goll SVP, Finance & Chief Accounting Officer Other Derivative Acquisition +7,411 --
2026-02-16 John Goll SVP, Finance & Chief Accounting Officer Other Derivative Acquisition +21,252 $32.38
2026-02-16 John Goll SVP, Finance & Chief Accounting Officer Derivative Exercise and Retained +653 --

Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。

报价时间 2026-10-16 19:30:04 · 仅供参考，不构成投资建议，也未考虑您的具体情况。

免疫核心 讨论区 0 条评论

发表评论